NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

HCW Biologics Inc. (HCWB) Stock Analysis

HCW Biologics Inc. (HCWB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

HCWB

$1.16

−$0.01 (−0.85%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HCWB with… →

HCWB Key Statistics

As of Oct 21, 2026
Trading
Open
$1.17
Previous Close
$1.17
Day's Range
1.15–1.21
52-Week Range
1.14–24.43
Volume
49.63K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.42
Valuation
Market Cap
$2.59M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.39
EPS (ttm)Profit attributable to each share over the last twelve months.
−19.84
Financials (FY)
Revenue (FY)
$54.23K−97.89%
Net Income (FY)
−$7.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
−83.05%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.24M
1-Year Return
−95.11%
Dividend and dates
Avg Volume
410.69K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, HCWB closed at $1.16, −95.11% over 1 year.

HCW Biologics Inc. (HCWB) has a market capitalization of $2.59M.

In fiscal 2025, HCWB reported revenue of $54.23K.

HCWB Stock Return by Calendar Year

HCW Biologics Inc. (HCWB) return since Jul 2021: what $10,000 became

1 year
$10,000 $489
−95.11%
5 years
$10,000 $18
−99.82%
Since Jul 2021
$10,000 $8
−99.92%

If you had invested $10,000 in HCW Biologics Inc. (HCWB) at the close on July 20, 2021, the earliest close on record here, it would have been worth $8 at the close on October 21, 2026: −99.92% in total, −74.47% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−80.09%
2025−94.56%
2024−63.59%
2023−36.03%
2022−17.46%
2021 (partial year)−63.17%

As of October 21, 2026.

HCWB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$54.23K−$7.96M−14,677.1%
2024$2.57M−$30.02M−1,169.7%
2023$2.84M−$24.99M−879.5%
2022$6.72M−$14.90M−221.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$54.23K$10.85K−$11.26M−$7.96M−14,677.1%
2024$2.57M$959.40K−$27.63M−$30.02M−1,169.7%
2023$2.84M$560.36K−$25.72M−$24.99M−879.5%
2022$6.72M$2.59M−$15.08M−$14.90M−221.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HCWB Valuation vs Biotechnology Median

Median of 608 stocks
MetricHCWBBiotechnology medianvs median
P/S ratio0.3913.300.0x the median
Profit margin−83.05%−38.31%44.7 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

HCW Biologics Inc. (HCWB) carries a market capitalisation of $2.59M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 35.

The 52-week range on file runs from $1.14 to $24.43. The most recent close on file for HCWB is $1.16, dated October 21, 2026. That is −$0.01 (−0.85%) against the previous close. The latest close sits 1.75% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $54.23K. That is −97.89% against the prior fiscal year, when revenue was $2.57M. The same year closed with a net loss of $7.96M. The reported profit margin is −83.05%. That is 44.7 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −19.84.

Across the 4 fiscal years on file, revenue moves from $6.72M in 2022 to $54.23K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 0.39 times revenue. On price-to-sales that is 0 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −95.11%. Across 5 years the annualized return works out at −71.70%. The reported beta is 2.42. Annualized volatility over the trailing 5 years is 237.52%.

Growth & Income

No dividend is on file for HCWB.

The strongest complete calendar year on file is 2022 at −17.46%; the weakest is 2025 at −94.56%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −80.09% year to date.

Peer Comparison

HCW Biologics Inc. (HCWB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
HCW Biologics Inc. HCWB $2.59M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. HCW Biologics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About HCW Biologics Inc.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Visit website →